Nuclia Waste

Main Menu

  • Home
  • Gross Margin
  • Forex Rates
  • Liquidity ratios
  • Waiver
  • Capital

Nuclia Waste

Nuclia Waste

  • Home
  • Gross Margin
  • Forex Rates
  • Liquidity ratios
  • Waiver
  • Capital
Gross Margin
Home›Gross Margin›Senzime secured sales in 16 hospitals in Q4 2021

Senzime secured sales in 16 hospitals in Q4 2021

By Ricky Bagby
January 3, 2022
31
0

Senzime develops and markets CE and FDA approved systems that confirm in real time the correct level of anesthetic before, during and after surgery to objectively determine when it is safe to wake the patient. Senzime’s unique TetraGraph system measures the depth of the patient’s muscle block digitally and with advanced algorithms using patented disposable sensors that are the lever of the business model.

The TetraGraph system is normally sold through distributors or direct sales, with hospitals being the end customers. Most appraisals are carried out in several stages during which value analysis committees often make final purchasing decisions based on clinical and financial justifications. The pandemic has resulted in longer sales processes for new technology, but Senzime now sees increased access to hospitals.

Senzime announced on November 12, 2021, that trials were underway or planned in more than 60 hospitals around the world.

At the end of december 2021, the number of ongoing or planned trials worldwide stood at 74 hospitals with a total future potential of 1,150 TetraGraph systems. Of these, some trials are planned or underway, others have been completed with positive results, and others are awaiting purchase approval.

During the fourth quarter of 2021, Senzime secured TetraGraph sales in 16 hospitals around the world. These hospitals are now gradually starting to purchase from Senzime. A review was lost for a competitor. The initial deal in each new hospital is typically a few TetraGraph systems on first order, with the goal of filling all of the operating rooms in each hospital over time.

As previously communicated Senzime estimates that the lifetime value (LTV) of a delivered TetraGraph, including the use of TetraSens sensors, is 250 TSEK over 5 years with a gross margin above 65%.

“We ended 2021 in a strong position and we are very confident until 2022. There are currently more TetraGraph evaluations going on than ever before. We note that a high proportion of these turn into sales and that the use of disposable TetraSens sensors is high. There are an average of 40 and 8 operating theaters per hospital in the United States and Europe, respectively, and our new MDR certified production facility guarantees the required delivery capacity ”, said Pia renaudin, CEO of Senzime

Related posts:

  1. Catchment Basin Market Dimension 2027
  2. Compass is funded as a know-how firm. Is it a, although? – Information Crunchbase
  3. Industrial Good Motors Market analysis report with Income, Gross Margin, Market Share and Future Prospect to 2026 with Aggressive Evaluation on (Rockwell Automation, Moog Animatics, Siemens, Robotshop, Common Electrical and others)
  4. Module Connector Market Measurement 2025
Tagsgross marginunited states
Previous Article

There is a lot to love about ...

Next Article

How does “Buy Now, Pay Later” Affect ...

Recent Posts

  • Dave Ramsey says debt consolidation solves nothing. Is he right ?
  • RBC BEARINGS INC – 10-K/Y OF OPERATIONS
  • Weakening USD Forex Market Regains Ground
  • (( 2022 )) Wyndham Championship: Live Now, Golf Line Today at TANTARA in San Francisco – August 4, 2022
  • Gold Dollar Holds Steady Ahead of ISM Services PMI as Yields Rise

Archives

  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • March 2021
  • February 2021

Categories

  • Capital
  • Forex Rates
  • Gross Margin
  • Liquidity ratios
  • Waiver
  • TERMS AND CONDITIONS
  • PRIVACY AND POLICY